- AstraZeneca’s diabetes drug Farxiga falls short in the global trial conducted to check its efficacy on COVID – 19 patients :
On 12 April 2021, AstraZeneca announced the failure of its diabetes drug in treating hospitalized COVID – 19 patients. The drug that was tested using this trial is called Farxiga.
The British drugmaker conducted the global trial on over 1,250 patients. This was carried out for around 30 days. The patients recruited for this study were hospitalized with COVID – 19. In addition to the drug Farxiga, these patients were also given the local care of standard throughout the study. [1]
Read about Which are the popular Pharma Brands prescribed for Diabetes?
The patients involved in this study were suffering from other comorbidities in addition to COVID – 19. The patients revealed to have a medical history of hypertension, cardiovascular disease, and heart failure. It also observed other conditions like type – 2 diabetes or chronic kidney disease in some patients.
The safety and tolerability of this medicine were consistent with the previously established safety profile of Farxiga. However, it failed to achieve statistical significance in cutting the risk of disease worsening, and death in COVID – 19 patients.
The pharma company stated that the trial failed to meet its main goals. It further added that it failed their expectations in treating COVID – 19 patients, who are at risk of developing serious complications.
Pingback: NMPA approves Tagrisso as an adjuvant therapy in early–stage lung cancer. > PharmaCampus